Regulated information

10 May 2023

Voting rights on 30 April 2023

Declaration relative to the total number of voting rights – April 2023

27 April 2023

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

Q1 2023 – Sales announcement

Q1 2023 – Sales presentation

Q1 2023 – Webcast replay

21 April 2023

Combined Shareholders’ Meeting of 31 May 2023

2023 Convening Notice

Voting form

Participate in the Shareholders’ Meeting

2022 Universal registration document – Ipsen

Report of the Board of Directors on the draft resolutions

Preliminary notice to the Meeting published at the BALO on 21 April 2023 – French version

Preliminary notice to the Meeting published at the BALO on 21 April 2023 – Translation for information

Documents availability – 2023 Ipsen Combined Shareholder’s Meeting

Statutory Auditors Report – 2022 Financial Statements

Statutory Auditors Report – 2022 Consolidated Financial Statements

Statutory Auditors’ special report on regulated agreements

Statutory Audit Report – resolutions 2023 CSM (in French)

Total number of voting rights and shares as of 21 April 2023

Convening Notice to the Meeting published at the BALO on 12 May 2023 – French version

Convening Notice to the Meeting published at the BALO on 12 May 2023 – Translation for information

11 April 2023

Voting rights on 31 March 2023

Declaration relative to the total number of voting rights – March 2023 (1)

06 April 2023

Ipsen publishes its 2022 Universal Registration Document

10 March 2023

Voting rights on 28 February 2023

Declaration relative to the total number of voting rights – February 2023

22 February 2023

Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023

Ipsen – Press Release Announcing Extension of Tender Offer for Albireo

16 February 2023

Ipsen – Consolidated Financial Statements – 2022

IPSEN_2022_CONSOLIDATED FINANCIAL STATEMENTS

10 February 2023

Voting rights on 31 January 2023

Declaration relative to the total number of voting rights and shares – January 2023

09 February 2023

Ipsen presents strong full-year 2022 results and guidance for 2023

FY 2022 – Results announcement

FY 2022 – Results presentation

FY 2022 – Results webcast

09 January 2023

Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases

Ipsen to acquire Albireo: announcement

Ipsen to acquire Albireo: presentation

06 January 2023

Voting rights on 31 December 2022

2022 12 31 Ipsen Voting rights

06 January 2023

Ipsen – Half year statement – 2022 12 31

2022 12 31 – IPSEN – PR Half year statement S2 2022 EN

09 December 2022

Voting rights on 30 November 2022

2022 11 30 Ipsen Voting rights

10 November 2022

Voting rights on 31 October 2022

2022 10 31 Ipsen Voting rights

27 October 2022

Ipsen delivers strong sales growth in the first nine months of 2022 and confirms its full-year guidance

YTD 2022 – Sales announcement

YTD 2022 – Sales presentation

YTD 2022 – Webcast

10 October 2022

Voting rights on 30 September 2022

2022 09 30 Ipsen Voting rights

09 September 2022

Voting rights on 31 August 2022

2022 08 31 Ipsen Voting rights

06 September 2022

Share buyback program – Ipsen reporting from 29 August to 02 September 2022 – Detailled

30 August 2022

Share buyback program – Ipsen reporting from 22 to 26 August 2022 – Detailled

23 August 2022

Share buyback program – Ipsen reporting from 15 to 19 August 2022 – Detailed

12 August 2022

Ipsen completes acquisition of Epizyme expanding its portfolio in oncology

Ipsen completes acquisition of Epizyme – 12 August 2022

10 August 2022

Voting rights on 31 July 2022

2022 07 31 Ipsen Voting rights

09 August 2022

Share buyback program – Ipsen reporting from 01 to 05 August 2022 – Detailed

05 August 2022

Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 August 2022

02 August 2022

Share buyback program – Ipsen reporting from 25 July to 29 July 2022 – Detailed

28 July 2022

Ipsen publishes its 2022 half year financial report

2022 Half-year financial report

28 July 2022

Ipsen delivers strong H1 2022 results and upgrades its full-year guidance

Ipsen – H1 2022 – Results announcement

Ipsen – H1 2022 – Results presentation

Ipsen - H1 2022 - Results webcast

26 July 2022

Share buyback program – Ipsen reporting from 18 July to 22 July 2022 – Detailed

19 July 2022

Share buyback program – Ipsen reporting from 11 July to 15 July 2022 – Detailed

06 July 2022

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF

06 July 2022

Ipsen – Half year statement – 2022 06 30

2022 06 30 – IPSEN – PR Half year statement S1 2022 en

05 July 2022

Share buyback program – Ipsen reporting from 27 june to 01 July 2022 – Agrege

Share buyback program – Ipsen reporting from 27 june to 01 July 2022 – Agregé

29 June 2022

Ipsen announces U.S. FDA Priority Review for palovarotene New Drug Application in patients with fibrodysplasia ossificans progressiva following resubmission

Ipsen FDA Priority Review for palovarotene NDA

28 June 2022

Share buyback program – Ipsen reporting from 20 june to 24 June 2022 – Detailed

27 June 2022

Ipsen to acquire Epizyme, expanding its portfolio in oncology

Ipsen to acquire Epizyme expanding its portfolio in oncology

Acquisition of Epizyme

Webcast Acquisition of Epizyme

21 June 2022

Share buyback program – Ipsen reporting from 13 june to 17 June 2022 – Detailed

14 June 2022

Share buyback program – Ipsen reporting from 06 june to 10 June 2022 – Detailed

10 June 2022

Voting rights on 31 May 2022

2022 05 31 Ipsen Voting rights

07 June 2022

Share buyback program – Ipsen reporting from 01 june to 03 June 2022 – Detailed

01 June 2022

Ipsen initiates a share buy-back program to cover its employee free share-allocation plan

27 May 2022

ASCO 2022: New Cabometyx® data show encouraging results in monotherapy and in combination across different tumor types including metastatic non-small cell lung cancer

Ipsen ASCO annual meeting press release ENG FINAL

24 May 2022

Press release post SM

Ipsen – Press release post SM – 24 May 2022

24 May 2022

Description of the share repurchase program

Ipsen – Description of the share repurchase program – 24 May 2022

10 May 2022

Voting rights on 30 April 2022

2022 04 30 Ipsen Voting rights

03 May 2022

Combined Shareholders’ Meeting of 24 May 2022

Documents availability – 2022 Ipsen Combined Shareholder’s Meeting

03 May 2022

Combined Shareholders’ Meeting of 24 May 2022

Documents availability – 2022 Ipsen Combined Shareholder’s Meeting

Convening notice – 2022 Ipsen Combined Shareholders’ Meeting

Voting form – 2022 Ipsen Combined Shareholders’ Meeting

Ipsen voting rights on 15 April 2022 – 2021 Ipsen Combined Shareholder’s Meeting

Auditors report on the resolutions submitted to the 2022 Shareholders’ Meeting (AGA)

03 May 2022

European Commission approves Cabometyx® as a second-line treatment for people living with radioactive iodine-refractory differentiated thyroid cancer

Ipsen_DTC EC approval_ENG

27 April 2022

Ipsen delivers a strong sales performance in the first quarter of 2022

Q1 2022 – Sales announcement

Q1 2022 – Sales presentation

Webcast Q1 2022

15 April 2022

Combined Shareholders’ Meeting of 24 May 2022

Preliminary notice to the Meeting published at the BALO on 15 April 2022 – Translation for information

Preliminary notice to the Meeting published at the BALO on 15 April 2022 – French version only

Report of the Board of Directors on the draft resolutions

Universal-registration-document-2021

14 April 2022

Ipsen publishes its 2021 Universal Registration Document

Universal registration document 2021 – AMF deposit

08 April 2022

Voting rights on 31 March 2022

2022 03 31 Ipsen Voting rights

25 March 2022

Ipsen receives positive CHMP opinion for Cabometyx® in radioactive iodine-refractory differentiated thyroid cancer

Ipsen – DTC CHMP – 25 March 2022

16 March 2022

Ipsen announces investment in new state-of-the-art electronic autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) designed to improve patient experience

Ipsen – Somatuline Autogel Depot Electronic Autoinjector – 16 March 2022

09 March 2022

Voting rights on 28 February 2022

2022 02 28 Ipsen Voting rights

08 March 2022

New patient-reported data demonstrated high satisfaction levels and fewer patients reporting injection-site pain with Somatuline® Autogel®/Somatuline® Depot (lanreotide)

Ipsen_ENETS 2022_ENG

16 February 2022

Ipsen – Consolidated Financial Statements – 2021

16 February 2022

Ipsen appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Ipsen – Nomination of Catherine Abi Habib EVP Strategy Transformation Digital – 16 February 2022

15 February 2022

Cabometyx® in combination with Opdivo® demonstrated continued survival and quality of life benefits with over two years of follow-up in the Phase III CheckMate -9ER trial

Ipsen – ASCO GU – 15 February 2022

11 February 2022

Ipsen presents strong full-year 2021 results and enters into exclusive negotiations to divest its Consumer Healthcare business

FY 2021 – Results announcement

FY 2021 - Results presentation

Webcast replay FY 2021

09 February 2022

Voting rights on 31 January 2022

2022 01 31 Ipsen Voting rights

24 January 2022

Health Canada approves Ipsen’s Sohonos (palovarotene capsules) as the first approved treatment for fibrodysplasia ossificans progressiva

Ipsen – Health Canada approves Ipsen’s Sohonos (palovarotene capsules) – 24 January 2022

21 January 2022

Ipsen nominates Karen Witts as new independent Board member

Ipsen – Nomination of Karen Witts as new independent Board member – 21 January 2022

17 January 2022

Ipsen – Half year statement – 2021 12 31

2021 12 31 – IPSEN – PR Half year statement S2 2021 en

12 January 2022

Voting rights on 31 December 2021

2021 12 31 Ipsen Voting rights

17 December 2021

Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership

Ipsen – Genfit Collaboration – 17 December 2021

Ipsen Expanding the scope in Rare Disease

09 December 2021

Voting rights on 30 November 2021

2021 11 30 Ipsen Voting rights

09 November 2021

Voting rights on 31 October 2021

2021 10 31 Ipsen Voting rights

27 October 2021

Ipsen Pledges Ambitious Action on Climate Change

ENG — Press Release – Ipsen Pledge to Climate 27102021_FINAL

21 October 2021

Ipsen delivers strong sales growth for the first nine months and improves its full-year guidance

YTD 2021 – Sales announcement

YTD 2021 – Sales presentation

Webcast replay Q3

18 October 2021

Ipsen adds another program into its pre-clinical R&D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3

Ipsen – Accent collaboration – 18 October 2021

11 October 2021

Share buyback program – Ipsen reporting from 19 to 23 July 2021 – Detailed

11 October 2021

Ipsen appoints Mari Scheiffele as EVP and President, Specialty Care International

Ipsen – Appointment of Mari Scheiffele – 11 October 2021

08 October 2021

Voting rights on 30 September 2021

2021 09 30 Ipsen Voting rights

18 September 2021

ESMO 2021: Cabometyx® demonstrates sustained 78% reduction in risk of disease progression or death in people living with uncommon form of thyroid cancer

Ipsen – ESMO 2021 – 18 February 2021

10 September 2021

Voting rights on 31 August 2021

2021 08 31 Ipsen Voting rights

31 August 2021

Share buyback program – Ipsen reporting from 23 to 25 August 2021

Share buyback program – Ipsen reporting from 23 to 25 August 2021 – Detailled

17 August 2021

Share buyback program – Ipsen reporting from 16 to 20 August 2021 – Detailed

17 August 2021

Share buyback program – Ipsen reporting from 09 to 13 August 2021 – Detailed

13 August 2021

Ipsen announces withdrawal of palovarotene NDA, confirming intention to re-submit following additional data analyses

Ipsen_Palovarotene NDA withdrawal_13 August

10 August 2021

Voting rights on 31 July 2021

03 August 2021

Share buyback program – Ipsen reporting from 26 to 30 July 2021 – Detailed

03 August 2021

Ipsen publishes its 2021 half year financial report

H1 2021 Half year financial report

02 August 2021

Ipsen and Exicure enter into exclusive collaboration targeting rare neurodegenerative disorders

Ipsen-Exicure collaboration-2 August 2021

29 July 2021

Ipsen delivers strong H1 2021 results and upgrades full-year guidance

H1 2021 – Results announcement

H1 2021 – Results presentation

Webcast replay H1

27 July 2021

Ipsen strengthens its pre-clinical Oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc. for BKX-001, targeting the apoptosis pathway

Ipsen-BAKX collaboration-27 July 2021

27 July 2021

Share buyback program – Ipsen reporting from 19 to 23 July 2021 – Detailed

20 July 2021

Share buyback program – Ipsen reporting from 12 july to 16 July 2021 – Aggregated

13 July 2021

Share buyback program – Ipsen reporting from 05 to 09 July 2021 – Detailed

09 July 2021

Voting rights on 30 June 2021

Ipsen – Voting rights – 2021 06 30

09 July 2021

Ipsen – Half year statement – 2021 06 30

IPSEN – 2021 06 30 – PR Half year statement S1 2021

06 July 2021

Share buyback program – Ipsen reporting from 28 june to 02 July 2021

29 June 2021

Share buyback program – Ipsen reporting from 21 june to 25 june 2021

Share buyback program – Ipsen reporting from 21 june to 25 June 2021 – Detailled

28 June 2021

Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer

Ipsen – Exelixis COSMIC-312 – 28 June 2021

22 June 2021

Share buyback program – Ipsen reporting from 14 june to 18 June 2021

Share-buyback-program-Ipsen-reporting-from-14-june-to-18-June-2021

15 June 2021

Share buyback program – Ipsen reporting from 7 june to 11 June 2021

10 June 2021

Voting rights on 31 May 2021

Ipsen – Voting rights – 2021 05 31

08 June 2021

Share buyback program – Ipsen reporting from 31 May to 4 June 2021

07 June 2021

Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021

Ipsen – Exelixis COSMIC-311 ASCO – 7 June 2021

02 June 2021

Ipsen initiates a share buy-back program to cover its performance and employee share plans

01 June 2021

Ipsen announces the launch of an Employee Shareholding Plan

28 May 2021

Ipsen confirms U.S. FDA accepts New Drug Application for palovarotene as the first potential treatment worldwide for fibrodysplasia ossificans progressiva (FOP)

Ipsen – Palovarotene FDA acceptance – 28 May 2021

27 May 2021

Press release post SM

Ipsen – Press release post SM – 27 May 2021

27 May 2021

Description of the share repurchase program

Ipsen – Description of the share repurchase program – 27 May 2021

12 May 2021

Monthly information relative to the total number of voting rights and shares composing the share capital

2021 04 30 Ipsen Voting rights

11 May 2021

Ipsen opts-in to join Exelixis with ongoing development of Cabometyx® for people living with a form of thyroid cancer, based on promising interim results

05 May 2021

Documents availbaility – Combined Shareholders’ Meeting of 27 May 2021

Documents availability – 2021 Ipsen Combined Shareholder’s Meeting

22 April 2021

Ipsen delivers encouraging sales growth in the first quarter of 2021 despite the pandemic, and confirms its full-year guidance

Q1 2021 – Sales announcement

Q1 2021 – Sales presentation

Webcast replay Q1

16 April 2021

Combined Shareholders’ Meeting of 27 May 2021

Preliminary notice to the Meeting published at the BALO on 19 April 2021 – Translation for information

Preliminary notice to the Meeting publsihed at the BALO on 19 April 2021 – French version only

Report of the Board of Directors on the draft resolutions

Universal-registration-document-2020

15 April 2021

Ipsen publishes its 2020 Universal Registration Document

Universal registration document 2020 – AMF deposit

09 April 2021

Monthly information relative to the total number of voting rights and shares composing the share capital

2021 03 31 Ipsen Voting rights

31 March 2021

European Commission approves Cabometyx® in combination with Opdivo® as a first-line treatment for patients living with advanced renal cell carcinoma

Ipsen – Cabometyx Opdivo EMA Release – 31 March 2021

12 March 2021

Monthly information relative to the total number of voting rights and shares composing the share capital

2021 02 28 Ipsen Voting rights

26 February 2021

Ipsen receives positive CHMP opinion recommending Cabometyx® in combination with Opdivo® as first-line treatment for patients living with advanced renal cell carcinoma

Ipsen – CHMP release – 26 February 2021

12 February 2021

Monthly information relative to the total number of voting rights and shares composing the share capital

2021 01 31 Ipsen Voting rights

11 February 2021

Ipsen delivered sales growth and margin expansion in 2020 – Focused on executing new strategy and delivering financial objectives in 2021

FY 2020 – Results announcement

FY 2020 – Results presentation

08 February 2021

New data from pivotal Phase III CheckMate -9ER trial of Cabometyx® in combination with Opdivo® showed significantly improved QoL benefits and sustained superior efficacy versus sunitinib in patients living with aRCC

Ipsen – ASCO GU 2021 – 8 February 2021

05 February 2021

Ipsen to showcase commitment to going beyond traditional outcome measures for patients living with renal cell carcinoma at ASCO GU 2021

Ipsen – ASCO GU 2021 – 5 February 2021

20 January 2021

Ipsen appoints Gwenan White as Executive Vice President, Communications and Public Affairs

Ipsen – Gwenan White nomation – 20 January 2021

19 January 2021

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF

20201231 – IPSEN – PR Half-year Statement S2 2020

15 January 2021

TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications

Ipsen – TOXINS 2021 – 15 January 2021

12 January 2021

Monthly information relative to the total number of voting rights and shares composing the share capital

2020 12 31 Ipsen Voting rights

09 December 2020

Monthly information relative to the total number of voting rights and shares composing the share capital

2020 11 30 Ipsen Voting rights

01 December 2020

Capital Markets Day 2020 – announcement

Capital Market Day 2020 – Announcement

Capital Market Day 2020 - Presentation

01 December 2020

Ipsen highlights new strategic priorities and provides mid-term financial outlook

Capital Market Day 2020 – Announcement

30 November 2020

Ipsen receives FDA Fast Track designation for investigational irinotecan liposome injection (ONIVYDE®) as a second-line monotherapy treatment for small cell lung cancer (SCLC)

Ipsen – Onivyde FDA Fast Track – 30 November 2020

10 November 2020

Monthly information relative to the total number of voting rights and shares composing the share capital

2020 10 31 Ipsen Voting rights

27 October 2020

Disclosure of transactions in own shares between 10/19/2020 and 10/20/2020

EN-web-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 19 October 2020 and 20 October 2020

22 October 2020

Ipsen delivers sales growth in the first nine months of 2020 despite the impact of COVID-19 and confirms its 2020 full year guidance

YTD 2020 – Sales announcement

YTD 2020 – Sales presentation

20 October 2020

Disclosure of transactions in own shares between 10/12/2020 and 10/16/2020

EN-Web- Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 12 October 2020 and 16 October 2020

13 October 2020

Disclosure of transactions in own shares between 10/05/2020 and 10/09/2020

EN-web-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 5 October 2020 and 9 October 2020

08 October 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company

2020 09 30 Ipsen Voting rights

08 October 2020

Ipsen to present 12 abstracts at the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress taking place jointly with the 35th Congress of the French Society of Physical and Rehabilitation Medicine (SOFMER)

Ipsen – WCNR Curtain Raiser – 8 October 2020

06 October 2020

Disclosure of transactions in own shares between 09/28/2020 and 10/02/2020

EN-Web-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 28 September 2020 and 2 October 2020

29 September 2020

Disclosure of transactions in own shares between 09/21/2020 and 09/25/2020

EN-web-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 21 september 2020 and 25 September 2020

25 September 2020

Ipsen appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer

Ipsen – ELT appointment – 25 September 2020

22 September 2020

Disclosure of transactions in own shares between 09/14/2020 and 09/18/2020

EN-BW-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 14 september 2020 and 18 September 2020

19 September 2020

ESMO 2020: Cabometyx® (cabozantinib) in combination with Opdivo® (nivolumab) demonstrates significant survival benefits in patients with advanced renal cell carcinoma in pivotal Phase III CheckMate -9ER trial

Ipsen – ESMO 2020 CheckMate9ER – 19 September 2020

18 September 2020

ESMO 2020: Phase II CLARINET FORTE results show increasing dose frequencies of Somatuline® Autogel® (lanreotide) allows patients with NETs to delay treatment escalation by up to 8.3 months

Ipsen – ESMO 2020 CLARINET FORTE release – 18 September 2020

15 September 2020

Disclosure of transactions in own shares between 07/09/2020 and 11/09/2020

EN-web-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 7 september 2020 and 11 September 2020

14 September 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company

2020 08 31 Ipsen Voting rights

14 September 2020

Ipsen showcases commitment to patient-centric advances in oncology with record number of abstracts to be presented at ESMO 2020 Virtual Congress

Ipsen – ESMO 2020 curtain raiser – 14 September 2020

10 September 2020

Ipsen to present new insights at ASBMR for potential treatment of ultra-rare disease fibrodysplasia ossificans progressiva (FOP), including global Phase III MOVE trial results

Ipsen – ASBMR 2020 – 10 September 2020

08 September 2020

Disclosure of transactions in own shares between 31/08/2020 and 04/09/2020

EN-web-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 31 August 2020 and 04 September 2020

01 September 2020

Disclosure of transactions in own shares between 24/08/2020 and 28/08/2020

EN-web-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 24 August 2020 and 28 August 2020

25 August 2020

Disclosure of transactions in own shares between 17/08/2020 and 21/08/2020

EN – web- Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 17 August 2020 and 21 August 2020

25 August 2020

Ipsen to present results from MOVE, the first global Phase III trial in fibrodysplasia ossificans progressiva (FOP), at ASBMR 2020 annual meeting

Ipsen – Global media release MOVE – 25 August 2020

18 August 2020

Disclosure of transactions in own shares between 10/08/2020 and 14/08/2020

EN-web-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 10 August 2020 and 14 August 2020

17 August 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company

2020 07 31 Ipsen Voting rights

11 August 2020

Disclosure of transactions in own shares between 03/08/2020 and 07/08/2020

EN-web-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 3 August 2020 and 7 August 2020

04 August 2020

Disclosure of transactions in own shares between 27/07/2020 and 31/07/2020

EN – Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 27 July 2020 and 31 July 2020

30 July 2020

Ipsen presents its half year 2020 results and reinstates guidance for full year 2020

H1 2020 – Results annoucement

H1 2020 – Results presentation

28 July 2020

Disclosure of transactions in own shares between 20/07/2020 and 24/07/2020

EN-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 20 July 2020 and 24 July 2020

21 July 2020

Disclosure of transactions in own shares between 13/07/2020 and 17/07/2020

EN – Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 13 July 2020 and 17 July 2020

13 July 2020

Disclosure of transactions in own shares between 06/07/2020 and 10/07/2020

EN-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 6 July 2020 and 10 July 2020

10 July 2020

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF

IPSEN – Half-year Statement Liquidity agreement S1 2020

10 July 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company

2020 06 30 Ipsen Voting rights

07 July 2020

Disclosure of transactions in own shares between 29/06/2020 and 03/07/2020

EN – Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 29 June 2020 and 3 July 2020

02 July 2020

Ipsen joins clinical collaboration to evaluate cabozantinib (CABOMETYX®) plus atezolizumab in metastatic non-small cell lung cancer and metastatic castration-resistant prostate cancer

Ipsen – Clinical collaboration to evaluate Cabometyx – 2 July 2020

01 July 2020

Ipsen presents Phase I/II clinical data evaluating liposomal irinotecan (Onivyde®) as an investigational first-line combination treatment for metastatic pancreatic cancer at the ESMO World Congress on Gastrointestinal Cancer

Ipsen – ESMO GI 2020 – 1 July 2020

30 June 2020

Disclosure of transactions in own shares between 22/06/2020 and 26/06/2020

ENGL-Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 22 June 2020 and 26 June 2020

23 June 2020

Disclosure of transactions in own shares between 15/06/2020 and 19/06/2020

ENGL – Buy-back programme – Art 5 of Market Abuse Regulation – IPSEN – 15 June 2020 and 19 June 2020

17 June 2020

Ipsen receives FDA Fast Track designation for liposomal irinotecan (ONIVYDE®) as a first-line combination treatment for metastatic pancreatic cancer

Ipsen – ONIVYDE FDA Fast Track – 17 June 2020

16 June 2020

Disclosure of transactions in own shares between 08/06/2020 and 12/06/2020

ENGL – Achats effectués – Art 5 Règlement Abus de Marché – IPSEN – du 08 June 2020 and 12 June 2020

12 June 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company

2020 05 31 Ipsen Voting rights

08 June 2020

Ipsen demonstrates continued commitment to rare diseases with eight abstracts accepted at ENDO 2020 published in the Journal of the Endocrine Society

Ipsen – ENDO 2020 – 8 June 2020

08 June 2020

Ipsen initiates a share buyback program to cover its share allocation plan

29 May 2020

Combined Shareholders’ Meeting of IPSEN S.A. held on 29 May 2020

PR Post Shareholders’ Meeting IPSEN 29 May 2020

29 May 2020

Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at the Combined Shareholders’ Meeting on 29 May 2020

Description of the share repurchase program proposed to the 2020 SM

28 May 2020

Ipsen appoints David Loew as Chief Executive Officer

Ipsen – David Loew CEO appointment – 28 May 2020

23 May 2020

New surveys show over 80% of patients with spasticity and cervical dystonia treated with botulinum toxin-A experience debilitating symptom recurrence

Ipsen – Carenity 2020 – 23 May 2020

Ipsen – Carenity inforgraphic – 23 May 2020

Ipsen – Carenity Cervical Dystonia inforgraphic – 23 May 2020

19 May 2020

Ipsen announces publication of first matching-adjusted indirect comparison of Cabometyx® (cabozantinib) versus regorafenib in advanced hepatocellular carcinoma in Advances in Therapy

Ipsen – MAIC – 19 May 2020

07 May 2020

20 April 2020

Ipsen announces positive topline results from pivotal Phase III CheckMate -9ER trial evaluating CABOMETYX® (cabozantinib) in combination with Opdivo® (nivolumab) in previously untreated advanced renal cell carcinoma

Ipsen – CheckMate9ER – 20 April 2020

16 April 2020

24 January 2020

Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria

Ipsen – Palovarotene – 24 January 2020

17 January 2020

Dysport® (clostridium botulinum type A toxin-haemagglutinin complex) now approved in the UK for symptomatic treatment of upper limb spasticity in children with cerebral palsy

Ipsen – Dysport – 6 January 2020

20 December 2019

16 October 2019

Monthly information regarding the total number of voting rights and total number of shares of the Company

2019 09 30 Ipsen Voting rights

16 October 2019

Ipsen and Blueprint Medicines announce exclusive global license agreement to develop and commercialize BLU-782 for the treatment of fibrodysplasia ossificans progressiva (FOP)

Download

26 September 2019

Ipsen showcases studies at the ESMO 2019 Congress highlighting progress in new approaches for difficult-to-treat cancers

23 September 2019

Ipsen announces positive results from Phase IIIb/IV ENGAGE study of the combination of Dysport® (abobotulinumtoxinA) with Guided Self-rehabilitation Contracts in adult patients with upper and lower limb spastic hemiparesis

20 September 2019

Ipsen to present new data at 13th Annual Conference of the International Liver Cancer Association (ILCA 2019)

Ipsen ILCA MAIC Press Release_EN

16 September 2019

Information regarding the total number of voting rights and shares

2019/08/31 Ipsen Voting rights

08 September 2019

Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE®) as a second-line treatment for small cell lung cancer (SCLC) at the IASLC 2019 World Conference on Lung Cancer

SEPT19_Ipsen Onivyde SCLC World Lung Press Release FINAL_EN

13 August 2019

Ipsen delivers strong results for the first half of 2019 with robust double-digit sales growth and improved Core Operating margin and upgrades its guidance for full year 2019

H1 2019 – Results announcement

H1 2019 – Results presentation

23 July 2019

Ipsen and Servier announce initial Phase 1/2 clinical data evaluating liposomal irinotecan (ONIVYDE®) as an investigational first-line treatment for metastatic pancreatic cancer at ESMO 21st World Congress on Gastrointestinal Cancer

190705_Ipsen Onivyde 1st Line World GI Data Presentation Press Release ENGLISH FINAL

02 July 2019

Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at the Combined Shareholders’ Meeting on 28 May 2019

Download

24 May 2019

New investigational clinical data for Ipsen’s oncology products in 11 solid tumor types to be presented at 2019 ASCO Annual Meeting

190522-Ipsen-Oncology-ASCO-Curtain-Raiser

14 May 2019

Ipsen to host an Investor Day to highlight its innovative R&D pipeline and provide financial outlook for 2022

Press release

Ipsen -Investor-Day-2019

13 May 2019

18 April 2019

Ipsen to Present Improvements to Somatuline® Autogel® Pre-filled Syringe at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference

ENG-Ipsen_ENETS_Abstract_FINAL

28 February 2019

Ipsen to Present New Data on Enhancement of Patient Care at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference

ENG-Ipsen_ENETS_CR_FINAL

25 February 2019

Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio

Ipsen-to-acquire-Clementia-Final

Ipsen-to-acquire-Clementia1

20 February 2019

Monthly information regarding the total number of voting rights and total number of shares of the Company

2019-01-31-Ipsen-Voting-rights

14 February 2019

Ipsen delivers strong 2018 results and expects continued sales and profit growth in 2019

FY 2018 – Results announcement

FY 2018 – Results presentation

29 January 2019

Exelixis and Ipsen initiate phase 3 pivotal trial (COSMIC-312) of cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced hepatocellular carcinoma

20 November 2018

Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)

15 November 2018

European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the treatment of hepatocellular carcinoma in adults previously treated with sorafenib

13 November 2018

Information regarding the total number of voting rights and shares

25 October 2018

Ipsen delivers strong sales growth of 20.2% for the third quarter of 2018 and confirms full year guidance

YTD 2018 – Sales announcement

YTD 2018 – Sales presentation

16 October 2018

Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) for the second-line treatment of patients with hepatocellular carcinoma (HCC)

21 September 2018

Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) for the second-line treatment of patients with hepatocellular carcinoma (HCC)

18 September 2018

Ipsen delivers strong results for the first half of 2018 with sales growth of 21.5% and upgrades its guidance for full year 2018

HY 2018 – Results announcement

HY 2018 – Results presentation

24 July 2018

Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at the Combined Shareholders’ Meeting on 30 May 2018

29 May 2018

European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma

09 May 2018

Information regarding the total number of voting rights and shares

26 April 2018

Ipsen reports strong first quarter 2018 sales growth of 23.1% at constant exchange rates

Q1 2018 – Sales announcement

Q1 2018 – Sales presentation

28 March 2018

Ipsen announces EMA validation of filing of a new application for additional indication for Cabometyx®, for patients with previously treated advanced Hepatocellular Carcinoma (HCC).

28 March 2018

Information regarding the total number of voting rights and shares

26 March 2018

Ipsen publishes its 2017 Registration Document

23 March 2018

Ipsen receives positive CHMP opinion for Cabometyx® (cabozantinib) for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma

13 March 2018

Ipsen delivers strong 2017 results with 21.1% sales growth and Core operating margin increase of 3.4 points and expects significant further growth in sales and margin in 2018

FY 2017 – Results announcement

FY 2017 – Results presentation

14 February 2018

Information regarding the total number of voting rights and shares

07 February 2018

Ipsen announces eight oral presentations from its Neurosciences portfolio at the 10th World Congress for Neurorehabilitation (WCNR)

29 January 2018

Ipsen and Exelixis announce phase 3 trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma

12 January 2018

Ipsen announces publication in Neurology of results of two studies demonstrating the efficacy and safety of Dysport® (abobotulinumtoxinA) in adult patients with lower limb spasticity

14 November 2017

Information regarding the total number of voting rights and shares

26 October 2017

Ipsen delivers strong sales growth of 22.6% for the third quarter of 2017 and confirms full year guidance

YTD 2017 – Sales announcement

16 October 2017

Ipsen announces that phase 3 CELESTIAL trial of cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma

11 October 2017

Information regarding the total number of voting rights and shares

19 September 2017

Ipsen receives approval from European Commission for Xermelo® (telotristat ethyl) for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue therapy

18 September 2017

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome

12 September 2017

Information regarding the total number of voting rights and shares

09 September 2017

Ipsen and Exelixis announce results from Phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma at ESMO 2017

08 September 2017

Ipsen receives validation from European Medicines Agency for the application of a new indication for Cabometyx® (cabozantinib) for first-line treatment of advanced renal cell carcinoma in adults

04 September 2017

Ipsen announces 16 abstract presentations of oncology portfolio at European Society of Medical Oncology congress

16 August 2017

Exelixis submits U.S. supplemental new drug application for Cabometyx^®(Cabozantinib) for the treatment of previously untreated advanced kidney cancer

15 August 2017

25 July 2017

Disclosure of transactions in own shares between 17-07-2017 and 21-07-2017

21 July 2017

Ipsen receives positive CHMP opinion for approval of Xermelo® (telotristat ethyl), for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue therapy

18 July 2017

Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETY or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma.

10 July 2017

Disclosure of transactions in own shares between 03-07-2017 and 07-07-2017

04 July 2017

Disclosure of transactions in own shares between 26-06-2017 and 30-06-2017

03 July 2017

Somatuline® Autogel® 120 mg receives Japanese approval for a new indication for the treatment of gastro-entero-pancreatic neuroendocrine tumors

30 June 2017

Ipsen announces co-promotion agreement with Saol Therapeutics to promote Dysport® (abobotulinumtoxinA) in the United States

27 June 2017

Disclosure of transactions in own shares between 19-06-2017 and 23-06-2017

21 June 2017

Disclosure of transactions in own shares between 12-06-2017 and 16-06-2017

19 June 2017

Ipsen and its partner Exelixis announce independent radiology committee review confirms results from Phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma

16 June 2017

Description of the regulatory framework of the share repurchase program proposed to the Combined Shareholders’ Meeting of 7 June 2017

IPSEN-Descriptif-programme-de-rachat-dactions-EN

11 May 2017

Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals

28 March 2017

The Ipsen Group publishes its 2016 Registration Document

13 March 2017

Ipsen announces MHRA approval of new indication for Decapeptyl® for the treatment of pre-menopausal women with early stage breast cancer

09 March 2017

Ipsen announces data presentations of lanreotide (Somatuline® Autogel®), telotristat ethyl and the investigational compound 177Lu-OPS201 at the European Neuroendocrine Tumor Society (ENETS) 2017 conference

02 March 2017

Ipsen appoints Benoit Hennion as Executive Vice President and President, Primary Care

01 March 2017

Ipsen’s Partner Lexicon Pharmaceuticals Announces That FDA Approves Lexicon Drug Xermelo™ (Telotristat ethyl) 250 mg as First and Only Oral Treatment for Carcinoid Syndrome Diarrhea in Cancer Patients with Metastatic Neuroendocrine Tumors.

27 February 2017

Ipsen’s partner Exelixis announces clinical collaboration with Bristol Myers Squibb for late-stage combination trial in first-line renal cell carcinoma.

23 February 2017

Ipsen delivers strong 2016 results and expects further sales growth and margin enhancement for 2017

FY 2016 – Results announcement

FY 2016 – Results presentation

13 February 2017

Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada

20 December 2016

The 2016 Georges Mathé Prize recognizes research on the immunological determinants of the response to breast cancer treatment

30205349966_1ac8f6f57f_k.jpg

18 October 2016

Disclosure of transactions in own shares between 10-10-2016 and 14-10-2016

11 October 2016

Disclosure of transactions in own shares between 03-10-2016 and 07-10-2016

10 October 2016

Ipsen and its partner Exelixis announce positive results from phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma presented at the European Society for Medical Oncology (ESMO) 2016 congress

10 October 2016

Information regarding the total number of voting rights and shares

07 October 2016

Ipsens’ partner, Exelixis, announced phase 1 trial results for cabozantinib in combination with nivolumab in advanced genitourinary tumors

04 October 2016

Disclosure of transactions in own shares between 26-09-2016 and 30-09-2016

27 September 2016

Ipsen announces data presentations of cabozantinib (Cabometyx™), lanreotide (Somatuline® Autogel®) and telotristat ethyl* at the European Society for Medical Oncology (ESMO) 2016 congress

27 September 2016

Disclosure of transactions in own shares between 19-09-2016 and 23-09-2016

20 September 2016

Disclosure of transactions in own shares between 12-09-2016 and 16-09-2016

14 September 2016

European Commission approves Ipsen’s Cabometyx™ (cabozantinib) Tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy

13 September 2016

Ipsen Announces FDA Approval of Dysport^® (abobotulinumtoxinA) for injection for the treatment of Lower Limb Spasticity in children aged two and older.

28 July 2016

Supplemental Application Filed for Somatuline^®in Japan for Additional Indication of Neuroendocrine Tumors

28 July 2016

Ipsen’s First Half 2016 Results

H1 2016 – Results announcement

H1 2016 – Results presentation

26 July 2016

Disclosure of transactions in own shares between 18-07-2016 and 22-07-2016

22 July 2016

Ipsen and its partner Exelixis receive positive CHMP opinion for Cabometyx™ (cabozantinib) for the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy

19 July 2016

Disclosure of transactions in own shares between 11-07-2016 and 15-07-2016

18 July 2016

Ipsen announces the acceptance by the European Medicines Agency of the marketing authorization application for telotristat etiprate to treat carcinoid syndrome caused by neuroendocrine tumors, in combination with somatostatin analogues

12 July 2016

Exelixis and its partner Ipsen announce positive overall survival results from subgroup analyses of phase 3 trial of CABOMETYX™ (cabozantinib) tablets in advanced renal cell carcinoma at 2016 ASCO annual meeting

05 June 2016

The Ipsen Group launches an employee shareholding plan

04 June 2016

Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO

31 May 2016

Combined Shareholders’ Meeting of 31 May 2016

31 May 2016

Eugenia Litz is appointed as Vice President Investor Relations of Ipsen

30 May 2016

Ipsen’s partner, Lexicon, announced FDA Priority Review of new drug application for telotristat etiprate for the treatment of carcinoid syndrome

26 May 2016

Description of the regulatory framework of the share repurchase program proposed to the Combined Shareholders’ Meeting of 31 May 2016

IPSEN-Descriptif-programme-de-rachat-dactions-EN

22 May 2016

Ipsen’s partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma

16 May 2016

Ipsen is pleased to announce that its partner Exelixis obtained FDA Approval of CABOMETYX™ (cabozantinib) tablets for patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy

07 April 2016

Information regarding the total number of voting rights and shares

04 April 2016

Dassault Systèmes and Ipsen sign collaborative agreement to develop innovative programs to support Ipsen’s drug discovery

30 March 2016

Exelixis and Ipsen enter into exclusive licensing agreement to commercialize and develop novel cancer therapy Cabozantinib in regions outside the United States, Canada and Japan

01 March 2016

Ipsen’s 2015 results and 2016 financial objectives

FY 2015 – Results announcement

FY 2015 – Results presentation

16 February 2016

Ipsen announces publication in Pediatrics of the results of the phase III randomized study showing the efficacy and safety of Dysport^® (abobotulinumtoxinA) in children with dynamic equinus foot deformity due to cerebral palsy

07 January 2016

Information regarding the total number of voting rights and shares

05 January 2016

Choose your location:

Choose a Language